Vaccines
The question is continually being raised: what offers superior protection, a vaccine against COVID-19 or natural immunity?
The patch is not only painless, it requires less vaccine to generate the same or greater effects.
Moderna seeks to invalidate two patents of Arbutus Biopharma Corp. The company hopes to appeal a preemptive challenge to the patents upheld by the U.S. Patent Trial and Appeals Board.
Data from the Phase II CYPRESS study presented at the virtual IDWeek (Infectious Disease Week) 2021 showed that the vaccine candidate provided a robust response against the infection.
Scientists are making progress toward a vaccine that could help protect against deadly overdoses.
First COVID-19, now cancer. BioNTech made history when its COVID-19 mRNA vaccine with partner Pfizer became the first ever approved.
The Pfizer-BioNTech booster shot is now authorized for people over 18 and 65 who are immunocompromised, at high risk due to their work or living situation and front-line healthcare workers.
The Phase II trial, VLA150202, evaluated the safety and immunogenicity of VLA15 on 246 healthy adults aged 18 to 65 years old across the United States.
Sputnik Vaccine’s 91.6% efficacy against the original COVID-19 strain has stood up to peer review in The Lancet. But what’s the controversy, lets’s check it out.
Pfizer and BioNTech share data with FDA on COVID-19 vaccines for younger children as Sanofi pivot on its mRNA COVID-19 vaccine, shifting focus toward other infectious diseases instead.
PRESS RELEASES